RARE — Ultragenyx Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $1.50bn
- $2.35bn
- $673.00m
Ultragenyx rises after FDA clears human trial for rare muscle disease drug
Ultragenyx's gene therapy helps control ammonia levels in late-stage study (updated)
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
U.S. RESEARCH ROUNDUP-Aerovironment, Bumble, Lumentum Holdings.
Column: Novartis quietly settles Henrietta Lacks suit as family’s legal push gains steam
Ultragenyx Q4 revenue rises 25% amid restructuring
Brief: Ultragenyx Q4 EPS USD -1.29
U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
Ultragenyx rises as gene therapy shows long‑term benefit in rare childhood brain disorder
Brief: Ultragenyx: Long-Term UX111 Data Shows Sustained CSF-HS Reductions, Multi-Domain Gains In Children With Sanfilippo Syndrome (Mps Iiia)
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule
Brief: Ultragenyx Provides Financial And Business Updates At J.P. Morgan Annual Healthcare Conference
Brief: Ultragenyx Completes Rolling Submission Of Biologics License Application To U.S. FDA For Dtx401 Aav Gene Therapy
U.S. RESEARCH ROUNDUP-Citigroup, DigitalBridge, Verisk Analytics
Ultragenyx hits record low after bone disease drug fails late-stage trials
Ultragenyx plummets after bone disease drug fails late-stage trials
Ultragenyx's bone disease drug fails to improve fracture rate in late-stage trials (updated)